Look Over Your Shoulder, Roche: Abbott’s Coming Up Behind
This article was originally published in Clinica
Executive Summary
Abbott Labs’ proposed $5.8bn acquisition of Alere will give its IVD sales a significant boost and propel the company up the ranks to become the sector’s No. 2, behind Roche.
You may also be interested in...
Despite Legal Dispute, Abbott Set To Buy Alere for $5.3bn
Soon before it was set to take Alere to court in an attempt to break out of an acquisition deal, Abbott has reversed course and plans to buy the company for half a billion less than the original price tag.
Alere Hit With Another Federal Subpoena, Casting More Doubt On Abbott Deal
The company says the matters under investigation are immaterial, but the stock market disagrees, taking about a billion dollars from embattled diagnostics company in under a half-hour.
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.